Mon.Apr 01, 2024

article thumbnail

European prosecutors take over investigation into deal for Pfizer COVID vaccines: Politico

Fierce Pharma

While the market for COVID-19 vaccines has been shrinking lately, an investigation into text messages between Pfizer CEO Albert Bourla and the European Commission’s President Ursula von der Leyen r | The European Public Prosecutor’s Office (EPPO) took over the investigation into COVID vaccine negotiations between the European Commission's president and Pfizer's CEO Albert Bourla, Politico reports.

Marketing 312
article thumbnail

FDA Clears the First Digital Therapeutic for Depression, But Will Payers Cover It?

MedCity News

The Otsuka Pharmaceutical and Click Therapeutics mobile app Rejoyn received FDA clearance for use as an adjunct to medication in the treatment of major depressive disorder. But Otsuka must overcome hurdles facing digital therapeutics products, which have yet to gain traction among payers. The post FDA Clears the First Digital Therapeutic for Depression, But Will Payers Cover It?

FDA 131
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Teva snares up to $150M in Abingworth funding to propel late-stage asthma rescue inhaler

Fierce Pharma

Shortly after Gilead Sciences teamed up with Carlyle’s Abingworth to fuel further research on its antibody-drug conjugate Trodelvy, Teva is following a similar pathway with an asthma resc | Shortly after Gilead Sciences teamed up with Carlyle’s Abingworth to fuel further research on its antibody-drug conjugate Trodelvy, Teva is following a similar pathway for an asthma rescue inhaler.

306
306
article thumbnail

AstraZeneca’s Rare Disease Pipeline Notches Another FDA Approval

MedCity News

The FDA approved AstraZeneca drug Voydeya as an add-on to standard therapies for paroxysmal nocturnal hemoglobinuria, a rare blood disorder. Alexion, now AstraZeneca’s rare disease subsidiary, added the small molecule to its pipeline via a 2019 acquisition.

FDA 115
article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

AstraZeneca CEO's 2024 pay proposal under fire from influential proxy advisers

Fierce Pharma

Like clockwork, AstraZeneca CEO Pascal Soriot’s pay is under fire again. | Like clockwork, AstraZeneca CEO Pascal Soriot’s pay is under fire again. The two most influential proxy advisory firms are rallying investors to vote against the 2024 pay proposal for Soriot at the company’s annual general meeting this month.

299
299
article thumbnail

Healthcare Docket: The Telehealth Boom is Inciting Action by Lawmakers and Fraudsters Alike

MedCity News

Ever since the Covid-19 pandemic pushed telehealth to the forefront of American healthcare modalities, the genie has emerged from the lamp to quite a mixed crowd of cheerleaders and cheaters.

More Trending

article thumbnail

With a rise in animal-human organ transplants, a drugmaker aims for a new standard of care

PharmaVoice

Eledon Therapeutics is developing a drug that could facilitate organ transplants from animals to humans as the procedure gains steam.

125
125
article thumbnail

AstraZeneca's rare disease add-on therapy Voydeya scores FDA nod

Fierce Pharma

With AstraZeneca’s dominance in the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) threatened by the recent approval of the first pill on the market for the condition, Novartis’ Fabha | With AstraZeneca’s dominance in the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) threatened by the recent approval of the first pill on the market for the condition, Novartis’ Fabhalta, AstraZeneca has answered in the United States for its add-on oral treatment in the indication.

FDA 256
article thumbnail

To advance women’s leadership, an effort ‘has to be purposeful,’ says EMD Serono exec

PharmaVoice

Gender diversity in leadership “doesn’t just happen,” — it requires institutional change, from investing in women’s startups to providing more generous family leave.

102
102
article thumbnail

Bavarian Nordic begins commercial launch of mpox vaccine Jynneos in US

Fierce Pharma

After years relying on the U.S. government to stockpile and distribute Jynneos, Bavarian Nordic is launching the mpox vaccine into the commercial market. | After years relying on the U.S. government to stockpile and distribute Jynneos, Bavarian Nordic is launching the mpox vaccine into the commercial market.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Merck gets grant for patent granted for tricyclic heterocycle compounds for treating HIV

Pharmaceutical Technology

Discover the groundbreaking patent by Merck & Co Inc for Tricyclic Heterocycle Compounds to combat HIV infection. Learn about the innovative formula and treatment methods for a potent solution in antiretroviral therapy.

98
article thumbnail

One-time gene therapy could improve wet AMD

European Pharmaceutical Review

New clinical data has demonstrated the potential of a one-time gene therapy for vision loss. REGENXBIO’s Phase I/IIa trial investigated the safety and tolerability of a single dose of subretinal ABBV-RGX-314 for wet age-related macular degeneration (wet AMD). The two-year data showed that ABBV-RGX-314 provided stable or improved visual acuity and retinal thickness in patients.

article thumbnail

FDA clears first DTx for depression from Otsuka, Click

pharmaphorum

Otsuka and Click Therapeutics’ Rejoyn has become the first prescription digital therapeutic (DTx) to be approved by the FDA for people with major depressive disorder

FDA 103
article thumbnail

‘Garbage In Is Garbage Out’: Why Healthcare AI Models Can Only Be As Good As The Data They’re Trained On

MedCity News

When developing or deploying new algorithms, hospitals and healthcare AI developers must pay close attention to the quality of training datasets, as well as take active steps to mitigate biases, said Divya Pathak, chief data officer at NYC Health + Hospitals, during a recent panel.

article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

US FDA grants fast track status to LISCure’s LB-P8 drug for PSC

Pharmaceutical Technology

FDA has granted fast track designation to LISCure Biosciences’ investigational drug LB-P8, for the treatment of PSC.

FDA 98
article thumbnail

Leqembi maintenance dose filed in US, but SC form delayed

pharmaphorum

Eisai has filed to extend the label for its Alzheimer’s drug Leqembi to include a once-monthly maintenance regimen

102
102
article thumbnail

‘Garbage In Is Garbage Out’: Why Healthcare AI Models Can Only Be As Good As The Data They’re Trained On

MedCity News

When developing or deploying new algorithms, hospitals and healthcare AI developers must pay close attention to the quality of training datasets, as well as take active steps to mitigate biases, said Divya Pathak, chief data officer at NYC Health + Hospitals, during a recent panel discussion. The post ‘Garbage In Is Garbage Out’: Why Healthcare AI Models Can Only Be As Good As The Data They’re Trained On appeared first on MedCity News.

article thumbnail

FDA clears AZ’s new PNH therapy Voydeya

pharmaphorum

AstraZeneca’s Voydeya has been approved by the FDA as an add-on to treatment with Soliris or Ultomiris for rare disease PNH

FDA 91
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

FDA Clears the First Digital Therapeutic for Depression, But Will Payers Cover It?

MedCity News

The Otsuka Pharmaceutical and Click Therapeutics mobile app Rejoyn received FDA clearance for use as an adjunct to medication in the treatment of major depressive disorder. But Otsuka must overcome hurdles facing digital therapeutics products, which have yet to gain traction among payers.

FDA 80
article thumbnail

How Dobbs v Jackson Women’s Health Organization Decision Influenced Self-Management Medication Use

Pharmaceutical Commerce

Cross-sectional study explores the impact of this monumental Supreme Court ruling.

article thumbnail

Search, Click, Enroll? What Clinical Trials Can Learn from E-commerce

MedCity News

Certain features, commonplace on most e-commerce platforms, can help transform clinical trial search databases.

Biopharma 102
article thumbnail

Fail-First Policies Are Harming Patients

Pharmaceutical Commerce

Patients should not have to wait to access the medication they need.

Patients 104
article thumbnail

Increase Revenue With Better, Faster Sales Onboarding

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

article thumbnail

AI Disruption is Coming. Are Healthcare Professionals Ready?

MedCity News

The modern healthcare environment will require ambidextrous experts in healthcare and AI

article thumbnail

Pharma Pulse 4/1/24: Uncertainties Associated with Accelerated Approval, Understanding DSCSA & more

Pharmaceutical Commerce

The latest news for pharma industry insiders.

Pharma 104
article thumbnail

Jubilant Pharmova gets grant for radiopharmaceutical composition for diagnostic imaging with stable attributes

Pharmaceutical Technology

Discover the innovative patent by Jubilant Pharmova Ltd for a stable radiopharmaceutical composition of tetrofosmin, ensuring high purity and effectiveness in diagnostic imaging.

52
article thumbnail

Field Sales Training: Essential Strategies and Tools for Success

Spotio

What comes to mind when you think about field sales training? Maybe you imagine stuffy conference rooms or outdated video lessons. Good news: it doesn’t have to be that way! You can design awesome training programs for your sales team. Doing so will improve the performance of your individual reps by an average of 20% ! (This is especially true when it comes to sales training for field techs, who need a solid understanding of the basics.

article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

FDA Approves Alexion’s Voydeya as Add-on Treatment for Adults with Extravascular Hemolysis

PharmExec

Treatment approved in combination with ravulizumab or eculizumab, representing minority demographic still suffering after receiving C5 inhibitor therapy for extravascular haemolysis.

FDA 52
article thumbnail

Complying with the CMS Interoperability and Prior Authorization Rule

Penrod

What CMS-0057-F Means for Health Insurance Companies In January 2024, CMS finalized its interoperability and prior authorization rule that requires various healthcare insurance entities to abide by the latest electronic health information exchange and prior authorization process for clinical services. These policies aim to enhance prior authorization and efficiency for care providers, payers and patients.

article thumbnail

Opening the Door for More NASH Patients

PharmExec

In this Pharmaceutical Executive video interview, Optum Rx clinical pharmacist, Arash Sadeghi, discusses developments for non-invasive diagnostics for liver disease and how such advancements could potentially impact the landscape of conditions like NASH.

article thumbnail

How to Automate Prior Authorization with Salesforce

Penrod

Challenges of Manual Prior Authorization The big irony is that most healthcare facilities still utilize manual prior authorization in today’s digital climate. This process burdens care providers, patients and insurance companies. According to the American Medical Association, 34% of healthcare providers say that manual PA has caused severe effects on patient outcomes, including injuries, disabilities and hospitalization.

article thumbnail

Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A